<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02210494</url>
  </required_header>
  <id_info>
    <org_study_id>EP202</org_study_id>
    <nct_id>NCT02210494</nct_id>
  </id_info>
  <brief_title>Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)</brief_title>
  <official_title>Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effexus Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Effexus Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety of Secretrol® in patients undergoing endoscopic mucosal resection for
      early adenocarcinoma of the esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse effect evaluation</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>EMR Ulcer</condition>
  <arm_group>
    <arm_group_label>Secretrol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Secretrol</intervention_name>
    <arm_group_label>Secretrol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Category 4-high-grade intraepithelial neoplasia

          -  Ages 18 or older

          -  signed Informed Consent Form

          -  signed Health Insurance Portability and Accountability Act (HIPAA) Authorization Form

        Exclusion Criteria:

          -  Clinically relevant data suggesting an unknown disease and requiring further
             evaluation by the Primary Investigator.

          -  Patients with renal failure or organ transplants.

          -  Patients who have known allergic reactions to Proton Pump Inhibitors (PPI).

          -  Participation in another study that would interfere with study endpoints within 30
             days prior to screening.

          -  Previous enrollment into the current study.

          -  Patient is the Investigator, his family member or employee at the investigational
             site.

          -  Patient known or suspected to be involved in alcohol or drug abuse.

          -  Known or suspected history of non-compliance with medications.

          -  Inability to follow the procedures of the study (e.g., due to language problems,
             psychological disorders)

          -  Patients receiving prohibited concomitant medications including PPIs, H2-blockers,
             sucralfate, misoprostol.

          -  Patients receiving prohibited concomitant medications including clopidogrel,
             ketoconazole, digoxin, diazepam, warfarin, phenytoin,
             emtricitabine/nelfinavir/tenofovir, atazanavir, citalopram,
             emtricitabine/rilpivirine/tenofovir, rilpivirine, nelfinavir, tricyclic
             antidepressants, baclofen, tacrolimus, cyclosporine, cilostazol, disulfiram,
             methotrexate, voriconazole.

          -  Pregnancy or intention to become pregnant during the course of study, breast feeding,
             or unwillingness to use a highly effective means of contraception (oral contraception
             or intrauterine device).

          -  Prescription Non-steroidal anti-inflammatory Drug (NSAID) or aspirin use: The patient
             must be able to stop these meds 1 week prior to screening and during treatment.

          -  History of upper gastrointestinal surgery, Zollinger-Ellison syndrome, esophageal
             stricture, peptic stricture, duodenal and ⁄ or gastric ulcer, esophageal motility
             disorders, Inflammatory Bowel Disease (IBD), AIDS, pancreatitis, malabsorption, severe
             cardiovascular or pulmonary disease, liver disease, active malignant disease,
             Scleroderma, diabetes mellitus, autonomic or peripheral neuropathy, myopathy,
             functional bowel disorder or any underlying disease or medication that might affect
             the lower esophageal sphincter pressure or increase the acid clearance time.

          -  Subject unable or unwilling to fully complete all stages of the study.

          -  Unable to sign informed consent or inability to give fully informed consent due to
             language problems, psychological disorder or mental deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>April Higbee, BSN</last_name>
    <phone>816 861-4700</phone>
    <phone_ext>57456</phone_ext>
    <email>April.Higbee@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Higbee, BSN</last_name>
      <phone>816-861-4700</phone>
      <phone_ext>57456</phone_ext>
    </contact>
    <investigator>
      <last_name>Prateek Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2014</study_first_submitted>
  <study_first_submitted_qc>August 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2014</study_first_posted>
  <last_update_submitted>August 4, 2014</last_update_submitted>
  <last_update_submitted_qc>August 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

